NasdaqGM:OCULPharmaceuticals
Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim
Earlier this year, Ocular Therapeutix reported that its Phase 3 SOL-1 trial for AXPAXLI in retinal disease met its primary endpoint, showing superiority to EYLEA and prompting plans to seek FDA approval based on this single study while its second Phase 3 trial, SOLAR, continues.
Management also addressed reported “floaters,” attributing them to harmless drug particles without vision impact, and argued that the highly treatment‑dependent, high‑vision SOL-1 population may understate how well...